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Abstract
Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor that is composed of a hypoxia-inducible a subunit (HIF-
1a and HIF-2a) and a constitutively expressed b subunit (HIF-1b). HIF mediates the adaptation of cells and tissues to low
oxygen concentrations. It also plays an important role in tumorigenesis and constitutes an important therapeutic target in
anti-tumor therapy. We have screened a number of reported HIF inhibitors for their effects on HIF-transcriptional activity
and found that the DNA damage inducing agents camptothecin and mitomycin C produced the most robust effects.
Camptothecin is a reported inhibitor of HIF-1a translation, while mitomycin C has been reported to induce p53-dependent
HIF-1a degradation. In this study we demonstrate that the inhibitory effect of mitomycin C on HIF-1a protein expression is
not dependent on p53 and protein degradation, but also involves HIF-1a translational regulation. Initiation of a DNA
damage response with the small molecule p53 activator NSC-652287 (RITA) has been reported to inhibit HIF-1a protein
synthesis by increasing the phosphorylation of eIF2a. However, we show here that even when eIF2a phosphorylation is
prevented, the DNA damage inducing drugs mitomycin C, camptothecin and NSC-652287 still inhibit HIF-1a protein
synthesis to the same extent. The inhibitory effects of camptothecin on HIF-1a expression but not that of mitomycin C and
NSC-652287 were dependent on cyclin-dependent kinase activity. In conclusion, specific types of DNA damage can bring
about selective inhibition of HIF-1a protein synthesis. Further characterization of the involved mechanisms may reveal
important novel therapeutic targets.
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Introduction
During tumorigenesis, occurrence of hypoxia contributes to
aggressive tumor progression, resistance to radiation and chemo-
therapy and poor prognosis. Hypoxia-inducible factor (HIF) is the
key transcription factor that mediates the adaptation of cells and
tissues to a hypoxic tumor environment. Its transcriptional targets
include numerous genes involved in angiogenesis, erythropoiesis,
glycolysis and cell proliferation [1,2]. HIF is known to be
upregulated in many human cancers, where it mediates the
adaptation to the hypoxic tumor environment resulting from rapid
tumor expansion that exceeds the development of new blood
vessels. HIF has also been shown to directly promote tumorigen-
esis, for instance by inducing genetic instability via transcriptional
downregulation of DNA mismatch repair proteins [3]. Further-
more, HIF has been reported to downregulate the intracellular
adhesion molecule E-cadherin, thus contributing to loss of cell-cell
adhesion in tumors [4–6], and to induce the expression of lysyl
oxidase, thereby promoting tumor cell migration and metastasis
[7]).
HIF is a heterodimer composed of a hypoxia-inducible a
subunit (HIF-1a and HIF-2a) and a constitutively expressed b
subunit (HIF-1b). It is regulated primarily through oxygen-
dependent changes in the stability of the a subunit. Under
normoxic conditions, HIFa is hydroxylated at two conserved
proline residues (Pro402 and Pro564 in HIF-1a) by a family of
oxygen- and 2-oxoglutarate-dependent prolyl 4-hydroxylases
[8,9]. Hydroxylated HIF-1a is recognized by the von Hippel-
Lindau (pVHL) protein and rapidly ubiquitinated by the
associated pVHL/Elongin B/C/Cul2 ubiquitin E3 ligase, fol-
lowed by its degradation by the 26S proteasome. The low
availability of oxygen under hypoxic conditions results in the
inhibition of prolyl hydroxylase activity and consequently in the
stabilization of HIF-1a protein. Upon nuclear translocation, HIF-
1a forms a heterodimeric transcription factor with HIF-1b which
binds to hypoxia-response elements and transactivates HIF target
genes.
In addition to the oxygen-dependent posttranslational regula-
tion, HIF-1a is also known to be regulated at various other levels,
including gene transcription, protein translation and pVHL-
independent protein degradation. For instance, insulin and growth
factors such as insulin-like growth factor 1 and 2 and heregulin are
known to increase HIF-1a protein concentrations by stimulating
its protein synthesis in a 59untranslated region (59UTR)-dependent
manner via activation of phosphatidylinositol 3-kinase, Akt and
mTOR signaling [10,11]. In addition, HIF-1a protein synthesis
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has been reported to be regulated by the RNA binding proteins
HuR and PTB as well as via stress-induced phosphorylation of
eIF2a [12–14]. There is also evidence for pathways that control
HIF-1a stability in an oxygen-independent manner. For instance,
Hsp90 inhibitors as well as the transcription factor FOXO-4 have
been reported to induce the degradation of HIF-1a in a pVHL-
independent manner [15–18].
Given the role of HIF in cancer, the development of HIF-
inhibitory agents is of great importance. Search for HIF inhibitors
and validation of their efficacy as anticancer agents is required.
Indeed, a number of novel small molecule inhibitors of HIF have
been identified through high-throughout screening of the National
Cancer Institute (NCI) chemical repository or natural product-like
combinatorial library [19–23]. In addition, various other agents
have been found to have HIF inhibitory activity, however, the
exact mechanism of action for most of these inhibitors remains
unknown. Elucidation of the involved molecular mechanisms is
critical to improve our understanding of the HIF signalling
pathways and to allow the development of more specific and
potent inhibitors. In this study, we have characterized and
investigated the mechanism of action of a number of reported
HIF inhibitors and identified the regulation of HIF-1a protein
synthesis as an important target of several HIF-inhibitory
compounds.
Methods
Cell lines, plasmid constructs, mutagenesis and
transfection of HEK293 cells
All used cell lines were obtained from commercial sources
(ATCC and Invitrogen). The expression vectors for wild type or
P402A/P564A HIF-1a, carrying a C-terminal V5 or FLAG tag
were as previously described [24]. Briefly, the HIF-1a coding
sequence was ligated into pcDNA3 or pcDNA3.1/Hygro using the
KpnI and XbaI sites, including a V5-tag immediately 59 to the
stop codon. For the 59UTR containing HIF-1a plasmids, the
59UTR (derived from IMAGE clone 3842146) was inserted into
the NheI site of pcDNA3.1/Hygro and the internal XhoI site in
the HIF-1a coding sequence. To generate the EGFP-HA-(HIF-
1a-59UTR) plasmid, the HIF-1a 59UTR (from 2260 to +132 bp)
was inserted upstream of the EGFP full length coding sequence
into pcDNA3. To generate the GADD34 C-terminal expression
plasmid, the coding sequence corresponding to amino acids 263 to
674 of human GADD34 was introduced into modified pcDNA3.1
including an N-terminal FLAG tag. For retroviral expression of
Bcl-xL, the Bcl-xL coding sequence was introduced into the EcoRI
and XhoI sites of the Puro-MaRX retroviral expression vector (a
kind gift by David Beach, Institute of Cell and Molecular Science,
London). Retrovirus was generated in 293-gag-pol cells and
pseudotyped with VSV-G.
The T-Rex system (Invitrogen) was used to generate cell lines
with tetracycline-inducible expression of dnUbc12-HA [25]. For
transfections, sub-confluent cells were transfected using Genejuice
(Novagen) according to the manufacturer’s instructions.
Hypoxia incubations
Hypoxia incubations were carried out at a controlled oxygen
tension (1%) using a Pro-ox 110 oxygen controller and Pro-ox in
vitro chamber (BioSpherix, Redfield, NY).
Immunoblotting
For immunoblotting, cells were washed with ice-cold PBS and
then lysed in triton X-100 containing lysis buffer, as previously
described [26]. Lysates were pre-cleared by centrifugation before
use for Western blotting. Equal amounts of protein from total
lysates were used for Western blot analysis. The following
antibodies were used: mouse monoclonal anti-HIF-1a (BD
Biosciences), mouse monoclonal anti-GAPDH (US Biological),
mouse monoclonal anti-a-tubulin (Molecular Probes), mouse
monoclonal anti-b-catenin (BD Biosciences), mouse monoclonal
anti-cdc6 (Santa Cruz), mouse monoclonal anti-Bcl-xL (Santa
Cruz), mouse monoclonal anti-GSK-3b (BD Biosciences), mouse
monoclonal anti-p53 (Sigma), rabbit polyclonal anti-NRF2 (Santa
Cruz), rabbit polyclonal anti-c-Myc (Santa Cruz), goat polyclonal
anti-CAND1 (Santa Cruz), rabbit polyclonal anti-Cul2 (Zymed),
goat polyclonal anti-Skp2 (Santa Cruz), mouse monoclonal anti-
BRCA1 (Calbiochem), rabbit polyclonal anti-phospho-Ser209-
eIF-4E (Cell Signaling), rabbit polyclonal anti-eIF-4E (Cell
Signaling), rabbit polyclonal anti-phospho-Ser51-eIF2a (Cell
Signaling), mouse monoclonal anti-eIF2a (Cell Signaling), mouse
monoclonal anti-HuR (Santa Cruz), mouse monoclonal anti-PTB
(Abcam), rabbit polyclonal anti-phospho-p70 S6 kinase (Cell
Signaling), rabbit polyclonal anti-p70 S6 kinase (Cell Signaling),
mouse monoclonal anti-phospho-Thr308-Akt (Cell Signaling),
mouse monoclonal anti-phospho-Ser473-Akt (Cell Signaling),
monoclonal anti-V5 (Serotec), monoclonal anti-FLAG M2
(Sigma), rat monoclonal anti-HA (clone 3F10) (Roche). All
Western blot results shown are representative of at least two
independent experiments.
Immunofluorescence
Cells were plated on coverslips and after treatment, the cells
were fixed with 4% formaldehyde for 15 min. The cells were
permeabilized using PBS containing 0.1% Triton X-100 and
blocked with PBS +0.05% Tween20+5% fetal bovine serum.
1:1500 dilutions of both primary and secondary antibody were
used. Subsequently, the coverslips were mounted onto glass slides
with VectorShield mounting media containing DAPI to label
nuclei and viewed using a fluorescent Leica DM IRB microscope
equipped with a Leica HCX PL FLUOTAR 63x/1.25 oil
objective.
Northern blot analysis
Cells were cultured in 60 mm plates and after drug treatment
for 10 to 12 hours, total RNA was isolated using TRIzol reagent
(Invitrogen). Equal amounts of denatured RNA were separated
using a formaldehyde/1% agarose gel, blotted onto Zeta-Probe
blotting membranes (Bio-Rad) and then crosslinked to the blot in a
UV Stratalinker (UVP, Upland, CA). The Northern blot was
probed with an [c-32P]dCTP – (3000 Ci/mMol, NEN, Boston,
MA) labeled HIF1a DNA probe at 65uC overnight using Church
hybridization solution (179.6 mM Na2HPO4, 91.25 mM
NaH2PO4, 7% SDS), washed and exposed to the phosphorimager
(FUJI).
siRNA-mediated gene silencing
For siRNA transfections, RNAi Max Lipofectamine (Invitrogen)
was used as transfection agent according to the manufacturer’s
instructions with the annealed predesigned siRNA duplexes
(Integrated DNA Technologies) at a final concentrations of
20 nM.
HRE-dependent luciferase reporter assays
HIF-1a reporter assays were carried out as previously described
[24] using a pGL3-HRE plasmid that was kindly provided by
Kaye Williams (The University of Manchester). Briefly, cells were
cultured in 12 well plates. At approximately 50% confluency, cells
HIF and DNA Damage Agents
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were transfected with 0.15 mg pGL3-HRE and 0.1 mg pRL-CMV
(Promega) or 0.15 mg empty pGL3 DNA per well for 24 hours.
Cells were then incubated at 1% O2 for 6 hours in the presence of
different inhibitors, and firefly and renilla luciferase activities were
assayed using the Steady-Glo or Dual Luciferase Assay System
(Promega). Each drug treatment was carried out in duplicates and
results shown are representative of three independent experiments.
Results and Discussion
Camptothecin, mitomycin C and YC-1 robustly inhibit
hypoxia-induced HIF transcriptional activity in HEK293
cells
Using a hypoxia-responsive luciferase reporter assay, we initially
screened a number of reported HIF-inhibitory compounds
[15,16,27–33] for their effects on HIF-transcriptional activity.
To rule out the possibility of non-specific inhibitory effects, the
luciferase activity of cells transfected with a pGL3 plasmid lacking
the hypoxia response element (HRE) was also determined. While
hypoxic incubation of cells transfected with pGL3-HRE resulted
in an approximately six-fold stimulation of luciferase activity
compared to cells incubated under normoxic conditions, no
significant change was observed in cells transfected with empty
pGL3 (Fig. 1a). Between the non-treated and each drug treatment
group, statistical comparison (Student’s t test) of the ratio of fold
stimulation obtained for cells transfected with pGL3-HRE to those
transfected with pGL3 empty vector showed that the guanylyl
cyclase activator YC-1, the topoisomerase I inhibitor camptothe-
cin, the DNA crosslinking agent mitomycin C, and the Hsp90
inhibitor geldanamycin significantly reduced (p,0.05) hypoxia-
dependent HIF-transcriptional activity (Fig. 1a). In contrast,
metavanadate, the p38 inhibitor SB203580 and the Ras inhibitor
S-trans,trans-farnesylthiosalicylic acid did not produce a significant
(p.0.05) reduction in luciferase activity.
We also investigated the role of glycogen synthase kinase-3,
which has previously been reported to mediate destabilization of
HIF-1a, thus leading to inhibition of HIF-1a dependent
transcriptional activity [34]. SB-415286 and SB-216763, two
selective GSK-3 inhibitors, did not increase HIF transcriptional
activity in hypoxia, but actually led to a decrease in activity by
27% and 16%, respectively (n = 3). This decrease was at least
partially due to non-specific drug effects as we also observed a
reduction in the luciferase activity of cells transfected with empty
control vector (14% and 11% for SB-415286 and SB-216763,
respectively). As shown in Fig. 1b, the GSK-3 inhibitors SB-
415263, SB-216763 and lithium chloride, while leading to the
expected upregulation of cytosolic b-catenin (a GSK-3 substrate
which is normally targeted for proteasome-dependent degradation
upon phosphorylation), also had no significant effect on the
hypoxia-induced HIF-1a protein stabilization. The inhibitors also
did not affect normoxic HIF-1a protein concentrations. Further-
more, overexpression of wild type or dominant-negative GSK-3b
at significant levels was without effect on HIF-1a protein
abundance in hypoxia, arguing against a direct role of GSK-3 in
regulating HIF-1a. In support of our results, a recent kinome
screen for modulators of HIF activity did not identify GSK-3 [35].
Thus, GSK-3 is likely not a universal regulator of HIF-1a protein
stability but may play a regulatory role in a cell type and tissue
specific manner [34].
To further confirm that the effect of the most potent HIF-
inhibitory agents mitomycin C, YC-1, camptothecin and gelda-
namycin was not due to non-specific effects or loss of cell viability,
cells were cotransfected with the pGL3-HRE reporter construct
and a Renilla luciferase control plasmid. As shown in Fig. 1c
(upper panel), the four inhibitors had no significant effect on
Renilla luciferase activity (statistical comparison of each treatment
group with the nontreated group yielded p values .0.05),
indicating that their effects are due to inhibition of HIF-
transcriptional activity. When determining the ratio of HRE-
dependent firefly luciferase activity over the activity of the
constitutively expressed Renilla luciferase, the inhibitory effects
of mitomycin C, YC-1 and camptothecin were still highly
significant (Fig. 1c, lower panel, p,0.05). In contrast, inhibition
by geldanamycin was no longer statistically significant (p=0.06).
We therefore focused on mitomycin C, camptothecin and YC-1 in
further studies.
Mitomycin C, camptothecin and YC-1 inhibit HIF-1a
protein accumulation
To investigate the mechanism of action of the three more potent
HIF inhibitors, we determined whether the effects on hypoxia-
induced HIF transcriptional activity are due to inhibition of
hypoxia-dependent HIF-1a protein accumulation. To this end,
HIF-1a protein was measured in HEK293 cells exposed to 1%
oxygen in the absence or presence of the three inhibitors. As
shown in Fig. 2a, all three compounds markedly reduced the HIF-
1a protein accumulation in hypoxia. Similarly, the compounds
also inhibited HIF-1a protein accumulation induced by prolyl
hydroxylase inhibition with desferrioxamine. All three drugs also
strongly inhibited HIF-1a protein when oxygen- and pVHL-
dependent HIF-1a ubiquitination was blocked (Fig. 2a). This was
achieved using a previously described cell line with tetracycline-
inducible expression of dominant-negative Ubc12, which results in
inhibition of all cullin E3 ubiquitin ligases, including the pVHL/
Elongin B/C/Cul2 E3 ligase [25]. The finding that YC-1,
mitomycin C and camptothecin could reduce HIF-1a protein
concentrations when prolyl hydroxylase- and pVHL-mediated
HIF-1a degradation was blocked suggests that these compounds
either inhibit HIF-1a mRNA or protein synthesis or that they
induce HIF-1a protein degradation that is independent of the
prolyl hydroxylase- and pVHL-mediated pathway.
All three compounds specifically inhibit protein synthesis
of HIF-1a
To determine the effects of the inhibitors on HIF-1a mRNA
synthesis and stability, we carried out Northern blot analyses. As
shown in Fig. 2b, YC-1 and camptothecin had no or only small
effects on the HIF-1a mRNA concentration, while mitomycin C
caused a 30% reduction in mRNA levels. However, statistical
analysis using a one-way ANOVA test showed that this reduction
was not significant (p.0.05). Also, a 30% reduction in HIF-1a
mRNA is unlikely to account for the much greater mitomycin C-
induced reduction in the HIF-1a protein concentration. In order
to confirm that the effect of mitomycin C is independent of
transcriptional downregulation of HIF-1a, we used actinomycin D
to block transcription. Addition of actinomycin D to cells caused a
paradoxical increase in the HIF-1a protein concentration (Fig. 2c),
consistent with a previous report [36]. Mitomycin C caused
proportionally the same decrease in HIF-1a protein expression in
the presence or absence of actinomycin D, suggesting that its effect
is independent of transcriptional regulation (Fig. 2c). Actinomycin
D partially blocked the HIF-1a inhibitory effect of camptothecin.
To determine the effects on HIF-1a protein synthesis, cells were
incubated in the presence of the 26S proteasome inhibitor MG-
132. Under these conditions, HIF-1a protein degradation that is
mediated through the prolyl hydroxylase and pVHL dependent as
well as through alternative mechanisms would be inhibited.
HIF and DNA Damage Agents
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10522
Figure 1. Effect of various HIF inhibitory compounds. (a) Hypoxia-dependent HIF-1a transcriptional activity was measured using HRE-dependent
reporter assays as described under Materials and Methods. HEK293 cells were incubated at 1% O2 for 6 hours in the presence of the various inhibitors
as indicated: mitomycin C (MC), 10 mg/ml; YC-1, 50 mM; S-trans,trans-farnesylthiosalicylic acid (FTS), 70 mM; SB203580, 20 mM; metavanadate, 50 mM;
camptothecin (CPT), 2 mM; geldanamycin (GA), 10 mM. (a) Luminescence was measured and fold stimulation was obtained by normalizing the relative
luciferase activity of cells cultured under hypoxic conditions to those of nontreated cells cultured under normoxic conditions. Results represent mean 6
SEM of three independent experiments. Student’s t test analysis of the ratio of fold stimulation obtained for cells transfected with pGL3-HRE to those
transfected with the promoter-less pGL3 empty vector showed that treatment with MC, YC-1, CPT and GA significantly (p,0.05, denoted as an asterisk
*, n= 3) reduced luciferase activity compared to untreated control. (b) HEK293 cells were transfected for two days with wild type or kinase-dead (K85R)
GSK-3b expression plasmids, or treated with 20 mM SB-415286, 5 mM SB-216763, or 30 mM LiCl for 6 hours. In the upper panel, the cells were incubated
at 1% O2 during the drug exposure. Cytosolic b-catenin concentrations were measured by lysing cells in hypotonic lysis buffer as previously described
[26] In the bottom panel, 200 mM desferrioxamine (DFO) was used as a positive control for normoxic HIF-1a induction and a HIF-1a reactive non-specific
(NS) band was used to demonstrate equal protein loading. (c,d) To study the effects of mitomycin C, YC-1, camptothecin and geldanamycin on HIF
transcriptional activity in more detail, firefly and renilla luciferase activity of cells cotransfected with pGL3-HRE and pRL-CMV and incubated under
hypoxic condition in the presence of MC, YC-1, CPT and GA (as in Fig. 1a) was measured. The renilla and firefly luciferase activities are shown in (c), the
ratio of firefly to renilla luciferase activity in (d). The results are expressed as fold stimulation relative to the activity in nontreated cells under normoxic
conditions. Statistical significance (p,0.05, n=3) is indicated with an asterisk in the bottom panel.
doi:10.1371/journal.pone.0010522.g001
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Figure 2. The effect of the mitomycin C, camptothecin and YC-1 is due to inhibition of HIF-1a protein synthesis. (a–b) HEK293 cells
were incubated for 10 hours in the presence of YC-1 (50 mM), mitomycin C (10 mg/ml), camptothecin (2 mM), and geldanamycin (10 mM) and cell
lysates subjected to Western blotting using the indicated antibodies. Cells were incubated at 1% oxygen during the last three hours of inhibitor
HIF and DNA Damage Agents
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Mitomycin C, camptothecin and YC-1 markedly reduced the
MG-132-induced accumulation of both the 120 kDa HIF-1a
protein as well as high molecular weight ubiquitinated HIF-1a
protein (Fig. 2d), indicating that these agents inhibit the synthesis
of new HIF-1a protein.
To confirm that the drug-induced decrease in the HIF-1a protein
abundance is specific, we first determined the effect of mitomycin C,
camptothecin and YC-1 on the steady state concentrations of a
number of other short lived cellular proteins under normoxic and
hypoxic conditions (Fig. 2e). The drugs were without effect on the
abundance of p53, b-catenin, NRF2, c-Myc, and the loading control
GAPDH. However, we found that cdc6 protein abundance was
reduced by mitomycin C and YC-1, and to a lesser degree by
camptothecin. Given that the effect of the drugs on the cdc6 protein
was prevented by addition of 26S proteasome inhibitor (data not
shown), it appears likely that they affect the protein via a different
mechanism. We also estimated the effects of the drugs on general
protein synthesis by measuring incorporation of L-[35S]-methio-
nine/L-[35S]-cysteine into cellular proteins. As shown in Supple-
mentary Fig. S1, both camptothecin and mitomycin C slightly
inhibited overall protein translation. However, this relatively small
inhibitory effect is unlikely to account for the marked reduction in
HIF-1a protein expression observed with both drugs.
Taken together, the results presented suggest that mitomycin C,
camptothecin and YC-1 are relatively selective inhibitors of HIF-
1a. All three drugs inhibit HIF-1a via effects on protein synthesis.
Our finding of camptothecin-induced inhibition of HIF-1a protein
synthesis agrees with previous studies [28,29]. In contrast,
mitomycin C was reported by Kaluzova et al. [33] to induce
p53-dependent degradation of HIF-1a, while different mecha-
nisms have been proposed for the action of YC-1. In further
studies, we focused on the mechanism of action of mitomycin C-
and camptothecin-mediated HIF inhibition.
Inhibition of HIF-1a protein accumulation by mitomycin
C is not due to an effect on protein degradation
Given that our conclusion with regards to mitomycin C-
mediated inhibition of HIF-1a protein accumulation contradicts a
previous study, we wanted to confirm that protein degradation is
not involved in the drug effect. We first determined the dose and
time dependence with which mitomycin C inhibited HIF-1a
protein expression (Supplementary Fig. S2a). Mitomycin C caused
a dose-dependent decrease in desferrioxamine-induced HIF-1a
protein expression, with a maximum effect observed at a
concentration of 10 mg/ml. A similar dose dependence for
mitomycin C-induced HIF-1a inhibition was observed under
hypoxic conditions (Supplementary Fig. S2b). To determine the
time dependence of the drug effect of mitomycin C, cells were
treated with desferrioxamine, which caused a time-dependent
increase in HIF-1a protein expression with a maximal effect at
approximately 10 hours (Supplementary Fig. S2c). Three hours
after desferrioxamine addition, mitomycin C was added and the
HIF-1a protein started to decrease gradually over time compared
to the control starting from 4 hours. At 10 hours of mitomycin C
treatment, HIF-1a decreased to non-induced control levels. In all
further experiments, we therefore used mitomycin C at a
concentration of 10 mg/ml for 8 to 12 hours.
To study the involvement of the 26S proteasome in mitomycin
C mediated HIF-1a inhibition, we used two specific inhibitors of
proteasomal protein degradation, epoxomicin and lactacystin.
Both drugs had no effect on the inhibition of desferrioxamine-
induced HIF-1a accumulation by mitomycin C (Fig. 3a). Similar-
ly, the proteasome inhibitor MG-132 and the inhibitors of
treatment (upper panel) or in the presence of 200 mM desferrioxamine (DFO) during the inhibitor treatment for 10 hours (middle panel), as indicated.
In the bottom panel, stably transfected cells with tetracycline inducible expression of dnUbc12 (5) were treated with 1 mg/ml tetracycline to block
VHL mediated HIF-1a degradation for 9 hours and cotreated with the indicated drugs for the last 5 hours, followed by Western blotting. The
presence of drugs during the induction time is indicated. (b) HIF-1amRNA concentrations after inhibitor treatment for 10 to 12 hours were measured
as described under Material and Methods. A representative autoradiogram is shown in the top panel. The bottom panel shows the average mRNA
levels for each inhibitor treatment expressed relative to those of DMSO control, as determined by densitometry of autoradiograms obtained from
three independent experiments. Statistical analysis using one-way ANOVA test across all treatment groups showed that all inhibitors exerted an
insignificant (p.0.05, n = 3) effect. (c) Cells were treated with 200 mM desferrioxamine and the indicated drugs in the absence or presence of 5 mM
actinomycin D for 8 hours, followed by Western blotting. (d) HIF-1a protein accumulation was measured by Western blotting after cotreatment of
cells with 25 mM MG-132 (added to cells for the last 4 hours) and the various inhibitors as indicated (added to cells for the last 9 hours). (e) To confirm
the specificity of the effect of mitomycin C, YC-1 and camptothecin, Western blotting for the indicated proteins was carried out after drug treatment
of cells for 11 hours and incubation at 1% oxygen during the last 4 hours, as indicated. Inhibitor concentrations in (b–e) were as in (a).
doi:10.1371/journal.pone.0010522.g002
Figure 3. Inhibition of HIF-1a protein accumulation by
mitomycin C is not due to an effect on protein degradation.
(a) HEK293 cells were treated with 200 mM desferrioxamine (DFO) and
10 mg/ml mitomycin C for 10.5 hours, as indicated, in the absence or
presence of the 26S proteasome inhibitors epoxomicin (1 mM) or
lactacystin (5 mM). (b) The cells were pretreated with 200 mM
desferrioxamine for three hours, followed by addition of 10 mg/ml
mitomycin and 40 mM cycloheximide for 8 hours.
doi:10.1371/journal.pone.0010522.g003
HIF and DNA Damage Agents
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lysosomal protein degradation, NH4Cl, chloroquine and bafilo-
mycin were without effect (data not shown). When using a HIF-1a
protein which was tagged with a FLAG- and a V5-tag at the N-
and C-terminus, we observed no cleavage products when probed
with either FLAG or V5 antibody (data not shown), indicating that
the effect of mitomycin C was not due to proteolytic cleavage of
HIF-1a protein. Consistent with this result, the protease inhibitors
calpeptin, pepstatin A and E-64 did not inhibit the mitomycin-
induced downregulation of endogenous HIF-1a (Supplementary
Fig. S3a). We also did not observe accumulation of HIF-1a in the
triton X-100-insoluble fraction upon treatment with mitomycin C
(or camptothecin) (Supplementary Fig. S3b). Thus, our data
suggest that inhibition of HIF-1a protein expression by mitomycin
C is not due to degradation by the 26S proteasome, lysosome or
other proteases or due to accumulation in insoluble aggregates. It
has been reported that in the presence of proteasome inhibitor,
mitomycin C decreases HIF-1a protein in the soluble fraction
because the protein becomes insoluble and accumulates in the
triton-insoluble fraction [33]. However, when using desferriox-
amine to induce HIF-1a protein in HEK293 cells, we did not
observe any accumulation of HIF-1a protein in the triton-
insoluble fraction upon adding proteasome inhibitor MG-132, in
the presence or absence of mitomycin C (data not shown).
We also tested whether mitomycin C still reduces HIF-1a protein
concentrations if new protein synthesis is inhibited with cyclohex-
imide. Addition of cycloheximide for 8 hours resulted in a significant
reduction in desferrioxamine-induced HIF-1a protein (Fig. 3b),
suggesting that HIF-1a still undergoes degradation in the presence
of the iron chelator. Mitomycin C did not further reduce the HIF-
1a protein abundance in the presence of cycloheximide, further
suggesting that the compound does not induce HIF-1a degradation.
It would be possible that mitomycin C-dependent HIF-1a requires
new transcription and/or translation (e.g. transcriptional upregula-
tion of genes that mediate HIF-1a degradation). However, the lack
of effect of actinomycin D on mitomycin C-mediated HIF-1a
inhibition (see Fig. 2c) argues against such a mechanism.
Inhibition of HIF-1a protein expression by mitomycin C,
but not by camptothecin is cell type dependent
We next tested the effect of mitomycin C and camptothecin on
desferrioxamine-induced HIF-1a protein expression in a number
of additional cell lines. Camptothecin inhibited HIF-1a expression
in all tested cell lines (Fig. 4). In contrast, mitomycin C was active
in the breast cancer cell line MCF7 and the colon cancer cell line
HT29, but not in MDA468 breast cancer and HCT116 colon
cancer cells. These results suggest that the effect of mitomycin C,
but not of camptothecin, is cell type dependent. When measuring
the cytotoxicity of mitomycin C using MTT assays, the drug
exhibited very similar potency in all four cell lines (data not
shown), indicating that the differential effect is not due to toxicity
or induction of apoptosis.
Mitomycin C-mediated HIF-1a degradation does not
require p53 transcriptional activity and is independent of
cellular apoptosis
Mitomycin C induced inhibition of HIF-1a protein expression
has been reported to be p53 dependent [33]. In contrast, our
results in HEK293 cells, in which p53 is inhibited due to the
constitutive expression of adenovirus proteins E1A and E1B [37–
40] suggest that the effect of mitomycin C does not require p53-
transcriptional activity. Furthermore, siRNA mediated silencing of
p53 in HEK293 cells did not affect mitomycin C induced
inhibition of HIF-1a expression (Fig. 5a). In addition, the
Figure 4. The effect of mitomycin C, camptothecin and etoposide on HIF-1a protein concentrations in different cell lines. The indicated
cell types were treated with 200 mM desferrioxamine, 10 mg/ml mitomycin, 2 mM camptothecin and 50 mM etoposide, as specified, for 10 to 14 hours.
doi:10.1371/journal.pone.0010522.g004
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inhibitory activity of mitomycin C towards HIF-1a protein
expression in the different cell lines used in Fig. 4 does not
correlate with their p53 status. Thus, mitomycin C was active in
MCF7 cells with wild type p53 and HT29 cells with mutant p53,
but was inactive in HCT116 cells with wild type p53 and
MDA468 with mutant p53. Finally, addition of pifithrin-a, a small
molecule inhibitor of p53 transcriptional activity, to wild type p53
expressing MCF7 cells did not affect HIF-1a inhibition by
mitomycin C (Fig. 5b).
The finding that camptothecin inhibited HIF-1a protein
expression in all cell lines indicates that its effect is also p53
independent. This is further supported by our finding that
etoposide, a DNA damaging agent with a related mechanism of
action to camptothecin (i.e. inhibition of topoisolerase II versus I)
which activates p53 via a similar DNA damage response, did not
affect HIF-1a protein expression (Fig. 4).
Mitomycin C induces cellular apoptosis via the intrinsic
pathway. To determine if mitomycin C induced HIF-1a inhibition
is a consequence of cellular apoptosis, a commonly used approach
would be to block the intrinsic apoptotic pathway by overexpres-
sion of antiapoptotic Bcl-2 family members. However, paradox-
ically, some Bcl-2 family members are known to have proapoptotic
effects in HEK293 cells. We therefore used MCF7 breast cancer
cells and overexpressed Bcl-xL. Retroviral transduction of Bcl-xL
into MCF-7 cells resulted in a pronounced protein overexpression
(Fig. 5c) and had a marked protective effect on mitomycin C
induced apoptosis (data not shown). However, inhibiting apoptosis
was without effect on mitomycin C mediated HIF-1a inhibition
(Fig. 5c), suggesting that the drug effect is not a consequence of
cellular apoptosis.
BRCA1 is a major mediator of cellular DNA damage repair
response downstream of the ATM, ATR and checkpoint kinases.
BRCA1 mutant cells have a 100 fold increased sensitivity to
mitomycin C [41], emphasizing the importance of BRCA1 in the
cellular response to the DNA crosslinking agent. We therefore
tested the involvement of BRCA1-mediated signalling events for
the effect of mitomycin C on HIF-1a protein expression by siRNA
mediated silencing of BRCA1 in HEK293 cells. As shown in
Fig. 5d, more than 90% knockdown of BRCA1 protein expression
was achieved. Although BRCA1 knockdown reduced the basal
expression of HIF-1a in the presence of desferrioxamine, it did not
prevent the inhibitory effect of mitomycin C (as well as that of
camptothecin). These results suggest that mitomcyin C induced
inhibition of HIF-1a protein synthesis is independent of a full
DNA damage response and may be mediated by signaling
mediators upstream from BRCA1 (e.g. through DNA damage
sensor and checkpoint kinases such as ATM, ATR and Chk2) or
alternative pathways.
Characterization of the effects of mitomycin C and
camptothecin on protein synthesis regulatory pathways
Protein synthesis is known to be regulated at multiple levels in
response to different signals and various types of cellular stress.
HIF-1a has been reported to be regulated at the level of protein
translation. For instance, insulin and growth factors are known to
increase HIF-1a protein synthesis [10,11]. Although the exact
mechanisms involved are currently not clear, the regulatory effect
is dependent on the HIF-1a 59untranslated region (59UTR) [10].
To test for the role of the 59UTR in mediating the inhibitory effect
of mitomycin C and camptothecin, a plasmid in which the human
HIF-1a 59UTR was inserted upstream of the coding sequence of
EGFP was transfected into HEK293 cells. However, treatment
with mitomycin C or camptothecin did not affect the EGFP
protein expression (Fig. 6a). We also determined the effect of the
59UTR in the context of the HIF-1a coding sequence using
transfected wild type and P402A/P564A mutant HIF-1a
(Fig. 6b,c). Mitomycin C also inhibited the expression of
transfected wild type and mutant HIF-1a, while camptothecin
gave variable results. However, we noted that both drugs also
reduced the concentrations of other short lived transfected
proteins, while not affecting the corresponding endogenous
proteins (data not shown). These results suggested that the effects
of the drugs on transfected proteins are at least partially due to
non-specific mechanisms. Nevertheless, if mitomycin C and
camptothecin regulate HIF-1a in a manner dependent on its
59UTR, differential effects would be expected when using HIF-1a
expression plasmids containing or lacking the 59UTR. When
measuring the inhibitory effects of the drugs using these plasmids,
no significant differences were observed for transfected HIF-1a
with or without the HIF-1a 59UTR (see Fig. 6b and c for wild type
and P402A/P564A HIF-1a, respectively). These results suggest
that the inhibitory effect of mitomycin C and camptothecin on
HIF-1a protein expression is independent of the 59UTR.
In a recent report, the RNA binding proteins HuR and PTB
were identified as important regulators of HIF-1a protein
translation [12]. We therefore determined whether the HIF-1a
inhibitors affected abundance or subcellular localization of both
PTP and HuR. As shown in Supplementary Fig. S4a, mitomycin
C, but not camptothecin increased the cellular HuR concentra-
tion, while none of the compounds afftected the PTB protein
concentration. Given that HuR increases HIF-1a translation [12],
the upregulation of HuR by mitomycin C is unlikely to account for
its HIF-1a inhibitory effect. Of note, cellular stress is known to
induce cytoplasmic translocation of HuR into granular structures.
Thus, we also determined the effect of mitomycin C and
camptothecin on HuR and PTB subcellular localization by
immunofluorescence. However, we found no significant difference
in cells treated with the inhibitors compared to control cells
(Supplementary Fig. S4b). In both treated and untreated cells,
PTB and HuR were localized to the nucleus and there was no
evidence for cytoplasmic accumulation of HuR in granules. We
conclude that the inhibitory effect of mitomycin C and
camptothecin on HIF-1a protein synthesis is unlikely to be
mediated by the RNA binding proteins HuR and PTB. However,
we cannot rule out the possibility that the drugs affect binding of
HuR and PTB to HIF-1a mRNA without affecting the cellular
concentration or localization of the RNA binding proteins.
A major pathway through which protein synthesis is controlled
is the Akt/mTOR pathway. For instance, a recently identified
HIF inhibitor, KCF72, has been reported to inhibit HIF-1a
protein synthesis and suppress the phosphorylation of eukaryotic
translation initiation factor 4E binding protein 1 (4E-BP1) and p70
Figure 5. Inhibition of HIF-1a by mitomycin C is independent of p53 and DNA damage-induced apoptosis. (a) HEK293 cells were
transfected with negative control or p53 siRNA for three days, followed by treatement with 200 mM desferrioxamine and 10 mg/ml mitomycin C for
10 hours and Western blotting of cell lysates with the indicated antibodies. (b,c) MCF7 cells were treated with 200 mM desferrioxamine and 10 mg/ml
mitomycin C for 14 hours as indicated, followed by Western blotting of cell lysates. In (b) pifithrin-a (25 mM) was included, as indicated. In (c) MCF7
cells were retrovirally transduced with Bcl-xL or empty vector, as indicated. (d) Brca1 was knocked down using siRNA for three days, as described
under Materials and Methods, followed by drug treatment (200 mM desferrioxamine, 10 mg/ml mitomycin, 2 mM camptothecin), as indicated.
doi:10.1371/journal.pone.0010522.g005
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S6 kinase, two key regulators of protein synthesis and substrates of
mTOR (23). We therefore determined the effect of the drugs on
the Akt/mTOR pathway using phosphospecific antibodies for Akt
and for mTOR substrates. Both drugs were without effect on Akt
phosphorylation at Thr308 and Ser473 (Supplementary Fig. S5a).
Furthermore, both mitomycin C and camptothecin did not
decrease, but actually increased p70 S6 kinase (Supplementary
Fig. S5b) and 4E-BP1 phosphorylation (data not shown). These
results indicate that inhibition of HIF-1a protein synthesis by
mitomycin C and camptothecin is independent of the Akt/mTOR
pathway. Both compounds also did not suppress phosphorylation
of eukaryotic initiation factor 4E (eIF-4E) at Ser209 (Supplemen-
tary Fig. S5c), which has recently been reported as a target of the
HIF-1a inhibitor 6a-tigloyloxychaparrinone [42].
Various cellular stress signals can induce the phosphorylation
of eIF2a at Ser51, thus leading to global inhibition of cellular
protein synthesis. Is has recently been reported that inhibition of
the 26S proteasome or activation of a p53 dependent DNA
damage response with 2,5-bis(5-hydroxymethyl-2-thienyl furan
(NSC-652287, RITA) lead to specific HIF-1a translational
inhibition via induction of eIF2a phosphorylation [13,14]. Given
the selectivity of the HIF-1a inhibitory effect of the drugs used in
these studies, it is currently not clear, however, why the
translation of other proteins is not affected. When measuring
eIF2a phosphorylation at Ser51 using a phosphospecific anti-
body, we found that mitomycin C and, to a lesser degree,
camptothecin induced phosphorylation of eIF2a without affecting
its total concentrations (Fig. 7a). Of note, desferrioxamine
treatment alone also resulted in marked eIF2a phosphorylation
(see Fig. 7b). We also confirmed induction of phosphorylated
eIF2a upon treatment with NSC-652287 (Fig. 7d). In subsequent
experiments we tested whether phosphorylation of eIF2a is
required for mitomycin C, camptothecin and NSC-652287
dependent inhibition of HIF-1a protein synthesis by overexpress-
ing an active C-terminal fragment of GADD34. This protein is a
substrate-specific regulatory subunit of the protein phosphatase 1
(PP1). The C-terminal GADD34 fragment is sufficient to recruit
PP1 to eIF2a and cause its dephosphorylation, as previously
shown in cells and in vivo in mice [43,44]. Overexpression of this
GADD34 construct indeed prevented basal as well as thapsi-
gargin-induced phosphorylation of eIF2a (Fig. 7b). It also
prevented mitomycin C induced phosphorylation of eIF2a
(Fig. 7b). We then determined the effect of overexpressing the
GADD34 plasmid on HIF-1a protein concentrations (Fig. 7c).
Figure 6. Mitomycin C and camptothecin mediated inhibition of HIF-1a protein synthesis is independent of the HIF-1a 59UTR. (a)
HEK293 cells were transfected with HIF-1a-59UTR-EGFP-HA plasmid for two days and then treated with 10 mg/ml mitomycin, 2 mM camptothecin,
followed by Western blotting with HA antibody. (b,c) Cells were transfected with the indicated plasmids and treated with the indicated drugs.
Myxothiazol, a mitochondrial complex III inhibitor and well established inhibitor of HIF-1a served as positive control in (b).
doi:10.1371/journal.pone.0010522.g006
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There was no effect on basal and desferrioxamine-induced HIF-
1a protein expression. GADD34 overexpression also had no
effect on the inhibition of HIF-1a by mitomycin C and
camptothecin. When using NSC-652287, a marked inhibitory
effect on desferrioxamine induced HIF-1a expression was
observed in the presence of the drug (Fig. 7d). However, this
was not affected by GADD34 overexpression, despite almost
complete inhibition of eIF2a phosphorylation. Taken together,
these results indicate that although the DNA damage inducing
agents induce the phosphorylation of eIF2a, this effect is unlikely
to account for their HIF-1a inhibitory effects.
The HIF-1a inhibitory effect of camptothecin requires
cyclin-dependent kinase (Cdk) activity
A recent study reported that camptothecin triggered transcrip-
tional stress leads to the induction of a novel transcript that is
antisense to human HIF-1a mRNA [45]. The induction of the
antisense transcript is dependent on topoisomerase 1 and Cdk
activity, but independent of a functional DNA damage response. To
determine whether this effect may account for the inhibitory effects of
camptothecin on HIF-1a protein translation, we cotreated cells with
camptothecin and the Cdk inhibitor 5,6-di-chloro-1-b-D-ribofura-
nosyl-benzimidazole (DRB). As shown in Fig. 8a, camptothecin
Figure 7. The role of eIF2a phosphorylation in the mechanism of action of HIF-1a inhibitors. (a) HEK293 cells treated with 10 mg/ml
mitomycin or 2 mM camptothecin for 10 hours followed by Western blotting with antibodies specific for Ser51 phosphorylated and total eIF2a. (b–d)
Cells were transfected with empty vector (control) or FLAG-GADD34 for two days followed by treatment with the indicated drugs: 1 mM thapsigargin,
200 mM desferrioxamine, 10 mg/ml mitomycin, 2 mM camptothecin, 1 mM NSC-652287. Treatment times were 10 hours. Western blotting of cell
lysates was performed using the indicated antibodies.
doi:10.1371/journal.pone.0010522.g007
Figure 8. Inhibition of Cdk activity reverses HIF-1a inhibition by camptothecin. (a) HEK293 cells were treated with 2 mM camptothecin and
50 mM DRB in hypoxia for 6 hours The lysates were used for Western blotting using HIF-1a antibody. A non-specific band detected with the HIF-1a
antibody served as loading control. (b,c) As in (a), the drug used concentrations were CoCl2 (200 mM), mitomycin C (10 mg/ml), NSC-652287 (1 mM).
doi:10.1371/journal.pone.0010522.g008
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prevented hypoxia induced HIF-1a expression, and this effect was
reversed by DRB. The Cdk inhibitor also prevented the effect of
camptothecin when HIF-1a was induced with CoCl2 (Fig. 8c). In
contrast, DRB did not result in a consistent rescue of the inhibition of
HIF-1a expression by mitomycin C and NSC-652287 (Fig. 8b and c).
Our results provide evidence that the inhibition of HIF-1a protein
synthesis by camptothecin may be the consequence of induction of a
HIF-1a antisense transcript [45]. This transcript comprises the HIF-
1a antisense sequence corresponding to parts of intron 1, exon 1 to
several hundred bases upstream of the transcription start site [45]. It is
possible that binding of the antisense transcript to the 59end of the
HIF-1a mRNA prevents efficient mRNA translation. However, it is
also possible that Cdk activity regulates HIF-1a translation in
response to DNA damaging agents via alternative mechanisms.
Conclusions
HIF has emerged as an important therapeutic target in anti-
cancer therapy. The oxygen sensitive HIF-1a subunit of the
dimeric HIF transcription factor is primarily regulated at the level
of its protein stability. However, in most cancers, normal
degradation of HIF-1a is prevented, due to mutations in VHL,
thus precluding HIF-1a ubiquitination by the VHL associated E3
ubiquitin ligase, or as a result of the inherently low oxygen
concentrations in tumor tissue, thus preventing oxygen dependent
prolyl hydroxylation of HIF-1a, which precludes binding to the
VHL protein. Two reported mechanisms through which HIF-1a
protein stability is regulated in an oxygen and VHL independent
manner are via phosphorylation of HIF-1a by the protein kinase
GSK-3 and by exposure to the DNA crosslinking agent mitomycin
C [33,34]. We show here that GSK-3 does not have universal
effects on HIF-1a protein concentrations in intact cells and that
mitomycin C functions by inhibiting new HIF-1a protein
synthesis.
Given the difficulty to therapeutically decrease HIF-1a protein
stability in tumors, most drug discovery efforts focus on inhibiting
HIF transcriptional activity [e.g. ref.19]. In addition, HIF-1a
protein translation has emerged as an important regulatory
mechanism and a number of compounds which target HIF-1a
protein synthesis have been identified. In this study we show that
in addition to camptothecin, the drugs mitomycin C and YC-1
also function by inhibiting HIF-1a translation. Although the Akt/
mTOR pathway and stress induced phosphorylation of eIF2a
have been shown to be important regulators of HIF-1a protein
synthesis rates, our data indicate that the DNA damaging agents
mitomycin C and camptothecin do not inhibit HIF-1a protein
expression via these pathways. Both of these pathways are global
regulators of protein synthesis rates. Thus, modulation of their
activity by different drugs would be unlikely to affect HIF-1a
protein concentrations selectively. It has been suggested that the
effect of translational inhibition is selective for HIF-1a because it is
more unstable than other proteins and changes in protein synthesis
rates thus become more apparent. However, we observed that
other unstable proteins are not affected by mitomycin C and
camptothecin treatment (see Fig. 2e). Furthermore, both drugs still
inhibited HIF-1a protein expression upon inhibiting its degrada-
tion with desferrioxamine.
Our results indicate the existence of HIF-1a specific mecha-
nisms that regulate protein translation in response to different
DNA damaging drugs. These regulatory mechanisms may involve
regulation by specific RNA binding proteins or elements in the
39UTR, including microRNA binding sites and/or induction of
antisense transcripts. Our results using BRCA1 knockdown (see
Fig. 5c) and inhibitors of DNA damage kinases ATM, ATR and
Chk1 (not shown) suggest that a functional DNA damage response
is not required for drug induced inhibition of HIF-1a protein
synthesis. HIF-1a translational inhibition in response to campto-
thecin and possibly other DNA damaging agents may be a
consequence of Cdk dependent induction of a recently identified
HIF-1a antisense transcript [45].
Supporting Information
Figure S1 Effect of camptothecin and mitomycin C on general
cellular protein synthesis. HEK293 cells were pretreated with
2 mM camptothecin and 10 mg/ml mitomycin C. After three
hours, the medium was changed to KREBS buffer +10% fetal calf
serum (and camptothecin or mitomycin C, respectively) to remove
amino acids. 60 min later, 20 mCi L-[35S]-methionine/L-[35S]-
cysteine Easy-Tag (PerkinElmer) was added and cells were rinsed
with PBS and lysed 15, 30, and 60 min after addition of the
labeled amino acids. Incorporation of L-[35S]-methionine/L-
[35S]-cysteine into cellular proteins was determined by SDS-
PAGE and autoradiography. In (b), 40 mM of the protein synthesis
inhibitor cycloheximide was added before L-[35S]-methionine/L-
[35S]-cysteine addition.
Found at: doi:10.1371/journal.pone.0010522.s001 (0.13 MB
TIF)
Figure S2 Dose and time dependence of mitomycin C-mediated
inhibition of HIF-1a.(a) HEK293 cells were treated for 11 hours
with increasing concentrations of mitomycin C (MC) in the
presence of 200 mM desferrioxamine (upper panel) or under
conditions of 1% oxygen (lower panel). (b) Cells were treated with
200 mM desferrioxamine. After 3 hours, mitomycin C (10 mg/ml)
was added where indicated (t = 0), and cells were lysed at t = 0,
2 h, 4 h, 7 h, 10 h. A representative Western blot is shown in the
left panel and a densitometry plot of the ratio of HIF-1a to a-
tubulin abundance in the right panel.
Found at: doi:10.1371/journal.pone.0010522.s002 (0.15 MB TIF)
Figure S3 Mitomycin C induced HIF-1a inhibition is not due to
protease-dependent cleavage or accumulation of the HIF-1a
protein in the triton-insoluble fraction.(a) HEK293 cells were
treated with 200 mM desferrioxamine and 10 mg/ml mitomycin in
the presence of 25 mM calpeptin or 10 mM pepstatin A plus
25 mM E-64 for 10 hours. (b) Cells were treated with the indicated
drugs. After cell lysis, equivalent volumes of the triton X-100
soluble and insoluble fractions were separated by SDS-PAGE and
analyzed with HIF-1a and a-tubulin antibodies.
Found at: doi:10.1371/journal.pone.0010522.s003 (0.12 MB TIF)
Figure S4 Effect of mitomycin C and camptothecin on HuR
and PTB concentrations and intracellular localization.HEK293
cells were treated with 10 mg/ml mitomycin or 2 mM camptothe-
cin for 6 hours, followed by Western blotting or immunofluores-
cence staining with HuR and PTB antibodies.
Found at: doi:10.1371/journal.pone.0010522.s004 (0.65 MB TIF)
Figure S5 Effect of mitomycin C and camptothecin on Akt, p70
S6 kinase and eIF-4E phosphorylation.HEK293 cells were treated
with the indicated drugs (10 mg/ml mitomycin, 2 mM camptothe-
cin, 50 mM YC-1 and 10 mM geldanamycin), followed by Western
blotting with the specified Akt, p70 S6 kinase and eIF-4E
antibodies.
Found at: doi:10.1371/journal.pone.0010522.s005 (0.11 MB TIF)
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